Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature

Journal of Medical Imaging and Radiation Oncology

Volumn 58, Issue 3, 2014, Pages 341-352

  Bester, Lourens ^a   Meteling, Baerbel ^a   Boshell, David ^a   Chua, Terence C ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

chemoembolisation; hepatic metastasis; radioembolisation; yttrium 90 microspheres

Indexed keywords

ANTINEOPLASTIC AGENT; YTTRIUM 90; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ARTICLE; BREAST CANCER; CANCER PALLIATIVE THERAPY; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; HEPATIC ARTERY; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; NEUROENDOCRINE TUMOR; PATIENT SELECTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; LIVER NEOPLASMS; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PROCEDURES; RADIOTHERAPY; SECONDARY; TREATMENT OUTCOME;

CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84901857660     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12163     Document Type: Article

References (79)

1. Lewandowski R, Geschwind J, Liapi E,. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011; 259: 641-657.
2. Liapi E, Geschwind J,. Chemoembolization for primary and metastatic liver cancer. The Cancer Journal 2010; 16: 156-162.
3. 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30: 571-592. (Pubitemid 350092259)
4. Wang S-C, Bester L, Burnes J, et al. Clinical care and technical recommendations for 90-yttrium microsphere treatment of liver cancer. J Med Imag Radiat Oncol 2010; 54: 178-187.
5. Salem R, Thurston M,. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies; part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006; 17: 1571-1594.
6. Cianni R, Urigo C, Notarianni E, et al. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med 2010; 115: 619-633.
7. Campbell AM, Bailey IH, Burton MA,. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2000; 45: 1023-1033. (Pubitemid 30196393)
8. Campbell AM, Bailey IH, Burton MA,. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001; 46: 487-498. (Pubitemid 32148511)
9. Gulec S, Mesoloras G, Dezarn W, McNeillie P, Kennedy A,. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 2007; 5: 15.
10. Tehranipour N, Al-Nahhas A, Canelo R, et al. Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology. Clin Nucl Med 2007; 32: 371-374. (Pubitemid 46659171)
11. Kennedy A, Salem R,. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer 2010; 16: 163-175.
12. Salem R, Lewandowski R, Atassi B,. Treatment of unresectable hepatocellular carcinoma with use of Y90 microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-1639. (Pubitemid 44431160)
13. Sangro B, Bilbao J, Boan J,. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800. (Pubitemid 44436697)
14. D'Avola D, Lnarrairaegui M, Martinez-Cuesta A, et al. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1683-1688.
15. Inarrairaegui M, Martinez-Cuesta A, Rodriguez M, et al. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 77: 1441-1448.
16. Salem R, Lewandowski R, Mulcahy M,. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
17. Sangro B, Carpanese L, Cianni R,. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878.
18. Kulik L, Carr B, Mulcahy M,. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81. (Pubitemid 351171043)
19. Salem R, Lewandowski R, Roberts C,. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15: 335-345. (Pubitemid 38451976)
20. Geschwind J, Salem R, Carr B,. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl. 1): S194-205. (Pubitemid 39423388)
21. Kulik L, Atassi B, van Holsbeeck L,. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94: 572-586. (Pubitemid 44851918)
22. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy vs. fluorouracil /leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88: 78-85. (Pubitemid 39536508)
23. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12: 1711-1720. (Pubitemid 34105661)
24. Sharma R, Van Hazel G, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25: 1099-1106. (Pubitemid 46596762)
25. Van Hazel G, Pavlakis N, Goldstein D, et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009; 27: 4089-4095.
26. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 1-8.
27. Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care vs. best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012; 35: 1066-1073.
28. Cosimelli M, Golfieri R, Cagol P, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103: 324-331.
29. Kennedy A, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65: 412-425.
30. Kennedy A,. Y90 microspheres for unresectable colorectal liver metastases: a multi-center study of 506 patients. Presented as a poster at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol 2012; 30 (Suppl.): 358.
31. 90Y- microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279.
32. Cao C, Yan T, Bester L, Liauw W, Morris D,. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97: 537-543.
33. King J, Quinn R, Glenn D, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921-929.
34. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008; 247: 1029-1035. (Pubitemid 351770424)
35. Coldwell D, Kennedy A, Nutting C,. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 2007; 69: 800-804. (Pubitemid 47418394)
36. Jakobs T, Hoffmann R-T, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008; 19: 683-690.
37. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 2007; 18: 621-628. (Pubitemid 46661173)
38. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S,. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401. (Pubitemid 13073577)
39. Yamada R, Nakatsuka H, Nakamura K,. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J 1980; 26: 81-96. (Pubitemid 11009683)
40. Coldwell D, Stokes K, Yakes W,. Embolotherapy: agents, clinical applications, and techniques. Radiographics 1994; 14: 623-643.
41. Llovet J, Real M, Montana X,. Arterial embolisation or chemoembolisation vs. symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739. (Pubitemid 34607087)
42. Lo C, Ngan H, Tso W,. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171. (Pubitemid 34454013)
43. Gupta S, Johnson M, Murthy R,. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumours: variables affecting response rates and survival. Cancer 2005; 104: 1590-10602.
44. Giroux M, Baum R, Soulen M,. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 2004; 15: 289-291. (Pubitemid 38316452)
45. Tellez C, Benson AB III, Lyster M,. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82: 1250-1259. (Pubitemid 28155386)
46. Geschwind J, Hong K, Georgiades C,. Utility of transcatheter arterial chemoembolization for liver dominant colorectal metastatic adenocarcinoma in the salvage setting. Paper presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 26-28 Jan 2006, San Francisco, CA.
47. Pelletier G, Roche A, Ink O,. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184.
48. Madden M, Krige J, Bailey S,. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34: 1598-1600. (Pubitemid 23341855)
49. Llovet J, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442. (Pubitemid 36152543)
50. Takayasu K, Arii S, Ikai I,. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469. (Pubitemid 44142456)
51. Vogl T, Gruber T, Naguib N,. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. Am J Roentgenol 2009; 193: 941-947.
52. Liapi E, Geschwind J, Vossen J,. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. Am J Roentgenol 2008; 190: 67-73.
53. Buijs M, Kamel I, Vossen J, Georgiades C, Hong K, Geschwind J,. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 2007; 18: 957-963. (Pubitemid 47126311)
54. Lammer J, Malagari K, Vogl T,. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
55. Dhanasekaran R,. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol 2010; 101: 476-480.
56. Salem R, Lewandowski R, Kulik L,. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507.
57. Lewandowski R, Kulik L, Riaz A,. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization vs. radioembolization. Am J Transplant 2009; 9: 1920-1928.
58. Taylor R, Tang Y, Gonzalez M, Stratford P, Lewis A,. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007; 30: 7-14. (Pubitemid 44908921)
59. Llovet J,. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2004; 7: 431-441. (Pubitemid 39585737)
60. Arii S, Yamaoka Y, Futagawa S, The Liver Cancer Study Group of Japan. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000; 32: 1224-1229.
61. Livraghi T, Meloni F, Morabito A,. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl 2004; 10 (2 Suppl. 1): S98-106. (Pubitemid 38240108)
62. Varela M, Real M, Burrel M,. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481. (Pubitemid 46201723)
63. Poon R, Tso W, Pang R,. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5: 1100-1108.
64. Malagari K, Alexopoulou E, Chatzimichail K,. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC Bead. Abdom Imaging 2008; 33: 512-519.
65. Reyes D, Vossen J, Kamel I,. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009; 15: 526-532.
66. Martin R, Joshi J, Robbins K,. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2010; 18: 192-198.
67. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) vs. intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1396.
68. De Baere T, Dechamps F, Teriitheau C,. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008; 19: 855-861.
69. Lencioni R, Llovet J, Han G,. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. ASCO Meeting Abstracts 2012; 30: LBA154.
70. Seinstra B, Defreyne L, Lambert B, et al. Transarterial radioembolization vs. chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials 2012; 13: 144. doi: 10.1186/1745-6215-13-144
71. Lance C, McLennan G, Obuchowski N, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1697-1705.
72. Xie F, Zang J, Guo X, et al. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2012; 138: 455-462.
73. 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-1639. (Pubitemid 44431160)
74. 90Y microspheres-safety, efficacy, and survival. Radiology 2008; 247: 507-515.
75. Jakobs T, Hoffmann R, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008; 19: 1187-1195.
76. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687-3694.
77. Bavisotto L, Patel N, Althaus S, et al. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res 1999; 5: 95-109. (Pubitemid 29045182)
78. Geschwind J,. Bevacizumab and chemoembolization in treating patients with liver cancer that cannot be removed by surgery. National Cancer Institute, Bethesda, MD, 2006.
79. Alberti C, Fiorentini G, Muzzio P, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 2011; 31: 4581-4587.